Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Very strange , even for ONC

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Feb 27, 2024 11:47am

135 Views

Post# 35901540

RE:RE:RE:RE:RE:RE:Very strange , even for ONC

So no one gets confused. You say they are late but only in comparison to other years timing. Late insinuates they are not abiding by rules and regulations. I know what you meant and it is interesting to speculate what is going on. This is their audited year end return which may have an extra component surrounding it that demands getting it right. GLTA

<< Previous

Bullboard Posts

Next >>

Crypto and blockchain stock ends year with a profit